7 unchanged sentences
(incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K, filed with the SEC on February 16, 2021).
+Added: 3.4 Amendment No.
+Added: 1 to the Amended and Restated Bylaws of Vallon Pharmaceuticals, Inc.
+Added: (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, filed with the SEC on May 18 2022).
+Added: 10.1 Placement Agency Agreement, dated May 13, 2022, between Vallon Pharmaceuticals, Inc.
+Added: and Ladenburg Thalmann & Co., Inc.
+Added: (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K, filed with the SEC on May 13, 2022).
+Added: 10.2 Non-Employee Director Compensation Program of Vallon Pharmaceuticals, Inc., effective on June 9, 2022.
31.1 Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
17 unchanged sentences
VALLON PHARMACEUTICALS, INC.
−Removed: May 9, 2022 By:
+Added: July 28, 2022 By:
/s/ Leanne M.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.